NASDAQ · SDGR
Healthcare · Medical - Healthcare Information Services
$30.24
Up+$1.22 (+4.20%)
Updated Sep 22, 2026, 3:28 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SDGR closed at $30.24 after 20 trading sessions, up 61.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $29.43 | $31.028 | $29.00 | $30.24 | 2.89M |
| Sep 18, 2026 | $29.32 | $30.22 | $28.5502 | $29.02 | 5.23M |
| Sep 17, 2026 | $24.09 | $30.41 | $24.09 | $30.24 | 9.03M |
| Sep 16, 2026 | $23.29 | $24.39 | $23.02 | $23.93 | 2.8M |
| Sep 15, 2026 | $20.78 | $23.71 | $20.34 | $23.25 | 3.8M |
| Sep 14, 2026 | $19.03 | $21.40 | $18.84 | $20.75 | 1.95M |
| Sep 11, 2026 | $18.93 | $19.03 | $18.63 | $19.02 | 464.98K |
| Sep 10, 2026 | $18.81 | $19.20 | $18.69 | $18.80 | 512.17K |
| Sep 9, 2026 | $19.88 | $20.005 | $19.09 | $19.20 | 758.94K |
| Sep 8, 2026 | $19.87 | $20.37 | $19.735 | $20.03 | 1.12M |
| Sep 4, 2026 | $20.58 | $20.67 | $19.685 | $20.09 | 877.06K |
| Sep 3, 2026 | $21.03 | $21.29 | $20.25 | $20.71 | 772.17K |
| Sep 2, 2026 | $20.67 | $21.3995 | $19.755 | $20.88 | 1.23M |
| Sep 1, 2026 | $19.25 | $20.99 | $19.2425 | $20.84 | 1.51M |
| Aug 31, 2026 | $19.58 | $19.65 | $19.13 | $19.50 | 652.39K |
| Aug 28, 2026 | $20.20 | $20.33 | $19.53 | $19.70 | 911.65K |
| Aug 27, 2026 | $19.49 | $20.41 | $19.4885 | $20.41 | 863.13K |
| Aug 26, 2026 | $19.725 | $19.98 | $19.30 | $19.47 | 752.13K |
| Aug 25, 2026 | $18.95 | $20.18 | $18.8595 | $19.99 | 899.85K |
| Aug 24, 2026 | $19.61 | $19.61 | $18.70 | $18.77 | 914.55K |
The latest Smart Investors Daily articles mentioning SDGR.
SDGR research
Company profile and research snapshot.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 17, 2026 | UBS | Neutral | — |
| Jan 8, 2026 | Keybanc | Overweight | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Jan 7, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
NEW YORK, September 09, 2026--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies.
Benzinga · Sep 9, 2026
Schrödinger, Inc. (NASDAQ:SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative
Yahoo · Sep 3, 2026
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Yahoo · Sep 1, 2026
NEW YORK, September 01, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SDGR.
